Trial Profile
A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms MDT-BRIDGE
- Sponsors AstraZeneca
- 04 Mar 2024 Planned End Date changed from 20 Sep 2027 to 27 Aug 2027.
- 04 Mar 2024 Planned primary completion date changed from 15 Mar 2027 to 1 Apr 2026.
- 04 Mar 2024 Status changed from not yet recruiting to recruiting.